Log In
BCIQ
Print this Print this
 

KBPA102

  Manage Alerts
Collapse Summary General Information
Company Kenta Biotech Ltd.
DescriptionHuman mAb against Psuedomonas aeruginosa generated using the MabIgX platform technology
Molecular Target P. aeruginosa LPS O6
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationPseudomonas
Indication DetailsTreat Pseudomonas aeruginosa infections
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today